secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001356576-24-000062
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus SPN-820 Phase 2a shows rapid antidepressant response: 50% MADRS rate at 4 hours
--------------------------------------------------------------------------------

- SPN-820 achieved 50.0% MADRS response rate and 35.0% remission rate at 4 hours post-dose in open-label Phase 2a study.
- By Day 10, response rate improved to 84.2% and remission to 63.2% in adults with major depressive disorder.
- Company notes positive early data; continues development and discussions with potential partners for Sunseeker asset.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000062/0001356576-24-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000062/supn-20241030.htm
  HTML page:      https://secwatch.observer/filing/0001356576-24-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer